This phase I trial is trying to determine the recommended dose of a new intravenous therapy (GSK3745417), when given alone or in combination with a type of immunotherapy, in patients with solid cancer types .
This trial is treating patients with solid cancers.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase I First Time in Human Open Label Study of GSK3745417 Administered With and Without Anticancer Agents in Participants With Advanced Solid Tumors
This is a dose escalation and expansion trial. In part 1
of the study, participants will receive an intravenous dose of GSK3745417 alone, at one week intervals. In part 2, GSK3745417 will be co-administered with 200mg IV pembrolizumab once every three weeks.
Recruiting Hospitals Read More